MARKET

AZN

AZN

AstraZeneca
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.88
+0.67
+1.21%
After Hours: 55.75 -0.13 -0.23% 17:53 05/17 EDT
OPEN
55.49
PREV CLOSE
55.21
HIGH
55.88
LOW
55.43
VOLUME
5.53M
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
46.48
MARKET CAP
146.71B
P/E (TTM)
36.96
1D
5D
1M
3M
1Y
5Y
US Poised To Dispatch 20M Additional COVID-19 Shots To Countries In Need: CNBC
Benzinga · 1h ago
Brazil to receive ingredients from China for 25 million vaccine shots in coming days
reuters.com · 3h ago
U.S. to ship additional 20M vaccine doses abroad abroad in June
The U.S. will ship 20M COVID-19 vaccine doses abroad next month, according to White House Press Secretary Jen Psaki.It is not known which countries will receive the vaccines, or what
Seekingalpha · 4h ago
UPDATE 2-Biden to send U.S.-authorized vaccines abroad for first time
reuters.com · 4h ago
UPDATE 3-Biden to send 20 mln doses of U.S.-authorized vaccines abroad for first time
reuters.com · 4h ago
UPDATE 1-Biden to announce U.S. will send 20 mln vaccines abroad by end of June
reuters.com · 4h ago
Biden to Send U.S.-Authorized Vaccines Abroad for First Time
President Joe Biden plans to send an additional 20 million doses of U.S. coronavirus vaccines abroad by the end of June -- including, for the first time, shots authorized for domestic use, where supply is beginning to outstrip demand.
Bloomberg · 5h ago
U.S. plans to send 20 million more COVID vaccine doses overseas: White House
The U.S. plans to send 20 million COVID-19 vaccine doses authorized for use in the U.S. to other countries battling the pandemic by the end of June, White...
marketwatch.com · 5h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZN. Analyze the recent business situations of AstraZeneca through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZN stock price target is 63.60 with a high estimate of 69.40 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 971
Institutional Holdings: 403.19M
% Owned: 15.36%
Shares Outstanding: 2.63B
TypeInstitutionsShares
Increased
213
20.20M
New
49
13.65M
Decreased
199
40.07M
Sold Out
78
1.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.61%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Leif Johansson
Chief Executive Officer/Executive Director
Pascal Soriot
Chief Financial Officer/Executive Director
Marc Dunoyer
Chief Human Resource Officer/General Counsel
Jeffrey Pott
Executive Vice President/Chief Compliance Officer
Katarina Ageborg
Executive Vice President
Jose Baselga
Executive Vice President
Pam Cheng
Executive Vice President
Ruud Dobber
Executive Vice President
David Fredrickson
Executive Vice President
Menelas Pangalos
Executive Vice President
Iskra Reic
Executive Vice President
Leon Wang
Secretary
Adrian Kemp
Non-Executive Director
Euan Ashley
Non-Executive Director
Diana Layfield
Non-Executive Director
Tony Mok
Non-Executive Director
Marcus Wallenberg
Non-Executive Independent Director
Philip Broadley
Non-Executive Director
Weiying Wang
Non-Executive Independent Director
Michel Demare
Independent Director
Narayan Seshadri
Non-Executive Independent Director
Deborah DiSanzo
Non-Executive Independent Director
Deborah Eldracher
Non-Executive Independent Director
Sherilyn McCoy
Non-Executive Independent Director
Nazneen Rahman
Declaration Date
Dividend Per Share
Ex-Div Date
02/21/2021
Dividend USD 0.93
02/25/2021
07/30/2020
Dividend USD 0.44
08/13/2020
--
Dividend USD 0.93
02/27/2020
--
Dividend USD 0.44
08/08/2019
--
Dividend USD 0.93
02/28/2019
07/26/2018
Dividend USD 0.44
08/09/2018
02/02/2018
Dividend USD 0.93
02/15/2018
07/28/2017
Dividend USD 0.44
08/09/2017
03/14/2017
Dividend USD 0.93
02/15/2017
09/08/2016
Dividend USD 0.44
08/10/2016
02/25/2016
Dividend USD 0.93
02/17/2016
07/30/2015
Dividend USD 0.44
08/12/2015
02/24/2015
Dividend USD 0.94
02/18/2015
07/31/2014
Dividend USD 0.9
08/13/2014
02/07/2014
Dividend USD 1.9
02/19/2014
08/01/2013
Dividend USD 0.9
08/14/2013
  • All
  • Financials
  • Insiders
More
About AZN
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Webull offers kinds of AstraZeneca plc (ADR) stock information, including NASDAQ:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.